Form 4 for INO INOVIO PHARMACEUTICALS, INC.
Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-26 · accession 0001055726-23-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-28 | 2023-02-26 | INO | Shea Jacqueline Elizabeth | CEO, Dir | F - Tax | $1.28 | -42.3K | 89.3K | -32% | -$54.1K |
| DM | 2023-02-28 | 2023-02-26 | INO | Shea Jacqueline Elizabeth | CEO, Dir | M - OptEx | — | +92.8K | 99.1K | +1,468% | — |
| DM | 2023-02-28 | 2023-02-26 | INO | Shea Jacqueline Elizabeth | CEO, Dir | M - OptEx | $0.00 | -92.8K | 22.5K | -80% | $0 |
| D | 2023-02-28 | 2023-02-27 | INO | Shea Jacqueline Elizabeth | CEO, Dir | A - Grant | $0.00 | +836.8K | 836.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-26 | F | D | 32,485 | $1.28 | 127,060 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-26 | M | A | 70,234 | — | 159,545 | D | — | — | (F3) Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| 3 | Common | Common Stock | 2023-02-26 | M | A | 22,544 | — | 99,099 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| 4 | Common | Common Stock | 2023-02-26 | F | D | 9,788 | $1.28 | 89,311 | D | — | — | |
| 5 | Derivative | Restricted Stock Unit | 2023-02-26 | M | D | 70,234 | $0.00 | 140,466 | D | — · — to — | 70,234 Common Stock | (F3) Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 210,700 restricted stock units, vesting as follows: 70,234 shares vested on February 26, 2023; 70,233 shares will vest on February 26, 2024; and 70,233 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| 6 | Derivative | Common Stock Option | 2023-02-27 | A | A | 836,800 | $0.00 | 836,800 | D | $1.24 · 2023-02-27 to 2033-02-27 | 836,800 Common Stock | (F5) The vesting schedule for the 836,800 options is as follows: 209,200 shares vested on February 27, 2023; 209,200 shares will vest on February 26, 2024; 209,200 shares will vest on February 26, 2025; and 209,200 shares will vest on February 26, 2026. |
| 7 | Derivative | Restricted Stock Unit | 2023-02-26 | M | D | 22,544 | $0.00 | 22,544 | D | — · — to — | 22,544 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |